These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 29506843)

  • 1. Pathologic response following treatment for locally advanced rectal cancer: Does location matter?
    Ward WH; Sigurdson ER; Esposito AC; Ruth KJ; Manstein SM; Sorenson EC; Wernick BD; Farma JM
    J Surg Res; 2018 Apr; 224():215-221. PubMed ID: 29506843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive Significance of Mucinous Histology on Pathologic Complete Response Rate Following Capecitabine-Based Neoadjuvant Chemoradiation in Rectal Cancer: a Comparative Study.
    Hosseini S; Nguyen N; Mohammadianpanah M; Mirzaei S; Bananzadeh AM
    J Gastrointest Cancer; 2019 Dec; 50(4):716-722. PubMed ID: 29984382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncologic outcomes after neoadjuvant chemoradiation followed by curative resection with tumor-specific mesorectal excision for fixed locally advanced rectal cancer: Impact of postirradiated pathologic downstaging on local recurrence and survival.
    Kim NK; Baik SH; Seong JS; Kim H; Roh JK; Lee KY; Sohn SK; Cho CH
    Ann Surg; 2006 Dec; 244(6):1024-30. PubMed ID: 17122629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CEA - a predictor for pathologic complete response after neoadjuvant therapy for rectal cancer.
    Wallin U; Rothenberger D; Lowry A; Luepker R; Mellgren A
    Dis Colon Rectum; 2013 Jul; 56(7):859-68. PubMed ID: 23739192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Whole-mount pathologic analysis of rectal cancer following neoadjuvant therapy: implications of margin status on long-term oncologic outcome.
    Mezhir JJ; Shia J; Riedel E; Temple LK; Nash GM; Weiser MR; Paty PB; Wong WD; Guillem JG
    Ann Surg; 2012 Aug; 256(2):274-9. PubMed ID: 22791103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distance to the anal verge is associated with pathologic complete response to neoadjuvant therapy in locally advanced rectal cancer.
    Patel SV; Roxburgh CS; Vakiani E; Shia J; Smith JJ; Temple LK; Paty P; Garcia-Aguilar J; Nash G; Guillem J; Wu A; Reyngold M; Weiser MR
    J Surg Oncol; 2016 Oct; 114(5):637-641. PubMed ID: 27641934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is final TNM staging a predictor for survival in locally advanced rectal cancer after preoperative chemoradiation therapy?
    Kuo LJ; Liu MC; Jian JJ; Horng CF; Cheng TI; Chen CM; Fang WT; Chung YL
    Ann Surg Oncol; 2007 Oct; 14(10):2766-72. PubMed ID: 17551794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparison of short-term efficacy and perioperative safety between neoadjuvant therapy and total neoadjuvant therapy in patients with locally advanced rectal cancer].
    Zhai ZW; Zhang KN; Wang C; Han JG; Ma HC; Wei GH; Yang Y; Wang ZJ
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):274-280. PubMed ID: 32192307
    [No Abstract]   [Full Text] [Related]  

  • 9. Pretreatment Tumor Thickness as a Predictor of Pathologic Complete Response to Neoadjuvant Chemoradiation Therapy for Stage II/III Rectal Adenocarcinoma.
    Xu B; Chen Y; Guo Y; Zhou D; Yue Z; Duan Q; Yang Y; Guan G; Chi P; Lin C
    Am J Clin Oncol; 2018 Jun; 41(6):601-606. PubMed ID: 27672742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Rectum-preserving surgery after consolidation neoadjuvant therapy or totally neoadjuvant therapy for low rectal cancer: a preliminary report].
    Huang Y; Huang SH; Chi P; Wang XJ; Lin HM; Lu XR; Ye DX; Lin Y; Deng Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):281-288. PubMed ID: 32192308
    [No Abstract]   [Full Text] [Related]  

  • 11. Complete pathologic response following preoperative chemoradiation therapy for middle to lower rectal cancer is not a prognostic factor for a better outcome.
    Pucciarelli S; Toppan P; Friso ML; Russo V; Pasetto L; Urso E; Marino F; Ambrosi A; Lise M
    Dis Colon Rectum; 2004 Nov; 47(11):1798-807. PubMed ID: 15622571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathologic Complete Response in Rectal Cancer: Can We Detect It? Lessons Learned From a Proposed Randomized Trial of Watch-and-Wait Treatment of Rectal Cancer.
    Nahas SC; Rizkallah Nahas CS; Sparapan Marques CF; Ribeiro U; Cotti GC; Imperiale AR; Capareli FC; Chih Chen AT; Hoff PM; Cecconello I
    Dis Colon Rectum; 2016 Apr; 59(4):255-63. PubMed ID: 26953983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Korean Society of Coloproctology (KSCP) trial of cONsolidation Chemotherapy for Locally advanced mid or low rectal cancer after neoadjUvant concurrent chemoraDiothErapy: a multicenter, randomized controlled trial (KONCLUDE).
    Kim CW; Kang BM; Kim IY; Kim JY; Park SJ; Park WC; Bae KB; Bae BN; Baek SK; Baik SH; Son GM; Lee YS; Lee SH
    BMC Cancer; 2018 May; 18(1):538. PubMed ID: 29739356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Analysis on efficacy and safety of total neoadjuvant therapy in patients with locally advanced rectal cancer with high risk factors].
    Ouyang GL; Meng WJ; Shu P; Deng XB; Wu B; Jiang D; Zhuang H; Shen YL; Zhou ZG; Wang ZQ; Wang X
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Apr; 22(4):349-356. PubMed ID: 31054549
    [No Abstract]   [Full Text] [Related]  

  • 15. Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management.
    Smith JJ; Chow OS; Gollub MJ; Nash GM; Temple LK; Weiser MR; Guillem JG; Paty PB; Avila K; Garcia-Aguilar J;
    BMC Cancer; 2015 Oct; 15():767. PubMed ID: 26497495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathologic stage is most prognostic of disease-free survival in locally advanced rectal cancer patients after preoperative chemoradiation.
    Quah HM; Chou JF; Gonen M; Shia J; Schrag D; Saltz LB; Goodman KA; Minsky BD; Wong WD; Weiser MR
    Cancer; 2008 Jul; 113(1):57-64. PubMed ID: 18442099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective pathologic analysis using whole-mount sections of rectal cancer following preoperative combined modality therapy: implications for sphincter preservation.
    Guillem JG; Chessin DB; Shia J; Suriawinata A; Riedel E; Moore HG; Minsky BD; Wong WD
    Ann Surg; 2007 Jan; 245(1):88-93. PubMed ID: 17197970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pathologic complete response of rectal cancer to preoperative combined-modality therapy results in improved oncological outcome compared with those who achieve no downstaging on the basis of preoperative endorectal ultrasonography.
    Stipa F; Chessin DB; Shia J; Paty PB; Weiser M; Temple LK; Minsky BD; Wong WD; Guillem JG
    Ann Surg Oncol; 2006 Aug; 13(8):1047-53. PubMed ID: 16865595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platelet and Neutrophil Counts as Predictive Markers of Neoadjuvant Therapy Efficacy in Rectal Cancer.
    Policicchio A; Mercier J; Digklia A; Voutsadakis IA
    J Gastrointest Cancer; 2019 Dec; 50(4):894-900. PubMed ID: 30353366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical implications of acellular mucin pools in resected rectal cancer with pathological complete response to neoadjuvant chemoradiation.
    de Campos-Lobato LF; Dietz DW; Stocchi L; Vogel JD; Lavery IC; Goldblum JR; Skacel M; Pelley RJ; Kalady MF
    Colorectal Dis; 2012 Jan; 14(1):62-7. PubMed ID: 21176057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.